Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A glioblastoma that is characterized by high cellularity, high mitotic activity, necrosis or microvascular proliferation and that lacks mutations in IDH genes.
Biomarker and diagnostic research for IDH-wildtype glioblastoma has been reported in the published literature.
4 clinical trials registered, 2 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 1 PHASE1, 3 NA. Research is primarily sponsored by academic and government institutions.
160 publications have been identified in PubMed for IDH-wildtype glioblastoma. Research spans Basic Science / Preclinical (31%), Diagnostic / Biomarker (20%), and Clinical Trial Publication (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 49 |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 11:48 PM UTC
Common questions about IDH-wildtype glioblastoma
31%
Testing and diagnosis research | 32 | 20% |
Clinical study results | 28 | 18% |
Disease patterns and progression | 21 | 13% |
Research summaries | 12 | 8% |
Patient case studies | 11 | 7% |
New treatment approaches | 7 | 4% |
Zhou DJ (2026). [PMID: 42083734](https://pubmed.ncbi.nlm.nih.gov/42083734/). *Ann Clin Transl Neurol*. [Epidemiology / Natural History]
Bayram S (2026). [PMID: 41752783](https://pubmed.ncbi.nlm.nih.gov/41752783/). *Medicina (Kaunas, Lithuania)*. [Epidemiology / Natural History]
Wang Y (2026). [PMID: 41811610](https://pubmed.ncbi.nlm.nih.gov/41811610/). *Journal of neuro-oncology*. [Basic Science / Preclinical]
Savani MR (2026). [PMID: 41137658](https://pubmed.ncbi.nlm.nih.gov/41137658/). *Neuro-oncology*. [Basic Science / Preclinical]
Strowd RE (2026). [PMID: 42058763](https://pubmed.ncbi.nlm.nih.gov/42058763/). *Neurooncol Adv*. [Clinical Trial Publication]
Zheng Z (2026). [PMID: 42196473](https://pubmed.ncbi.nlm.nih.gov/42196473/). *Int J Mol Sci*. [Review / Meta-Analysis]
Roncelli F (2026). [PMID: 41794965](https://pubmed.ncbi.nlm.nih.gov/41794965/). *J Neurooncol*. [Diagnostic / Biomarker]
Radu R (2026). [PMID: 41596752](https://pubmed.ncbi.nlm.nih.gov/41596752/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Hu Z (2026). [PMID: 42079621](https://pubmed.ncbi.nlm.nih.gov/42079621/). *Front Immunol*. [Review / Meta-Analysis]
Friedes C (2026). [PMID: 42033515](https://pubmed.ncbi.nlm.nih.gov/42033515/). *J Neurooncol*. [Basic Science / Preclinical]